GALAPAGOS NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.18 EUR | -0.73% |
|
-4.63% | -26.52% |
Chart calendar Galapagos NV
b1763bc856db31b8460cb63a3d67377f.X4MhMmTw-zK7kkEK16UcC4qXKwsjc2qB2-NPvVDPpq0.O8tXVwexsHnw23lHpvNqPMb9bX1tAj3qvKUI6Da30sYFsRRDFIiaefjlJg~8ec37f805198b215a6fe05ab14a8a0e5
Upcoming events on Galapagos NV
Past events on Galapagos NV
| 2024-04-17 08:06 am | European Society for Blood and Marrow Transplantation Meeting - Oral Number: OS16-05 |
| 2024-04-17 07:57 am | European Society for Blood and Marrow Transplantation Congress - Oral Number: OS16-04 |
| 2024-04-15 01:00 pm | European Society for Blood and Marrow Transplantation Congress - Poster Number: A073 |
| 2024-04-14 03:30 am | European Society for Blood and Marrow Transplantation Congress - Poster number: P049 |
| 2024-03-13 | Barclays Global Healthcare Conference |
| 2024-03-04 | TD Cowen Health Care Conference |
| 2024-02-23 08:00 am | Q4 2023 Earnings Call |
| 2024-02-22 04:01 pm | Q4 2023 Earnings Release |
| 2024-02-17 02:30 am | EBMT EHA European CAR T Cell Meeting - Poster No: AS-CART-2024-00103 |
| 2024-02-16 12:38 pm | EBMT EHA European CAR T Cell Meeting - Oral No: AS-CART-2024-00099 |
| 2024-02-15 02:15 pm | EBMT EHA European CAR T Cell Meeting - Poster No: AS-CART-2024-00104 |
| 2024-02-15 01:45 pm | EBMT EHA European CAR T Cell Meeting - Poster Number: AS-CART-2024-00090 |
| 2024-02-15 01:45 pm | EBMT EHA European CAR T Cell Meeting - Poster No: AS-CART-2024-00090 |
| 2024-02-14 | European Society for Blood and Marrow Transplantation -European Hematology Association Meeting |
| 2024-01-25 | Degroof Petercam Healthcare Seminar |
| 2024-01-24 | Barclays Healthcare C-suite Conference |
| 2024-01-07 | JPMorgan Healthcare Conference |
| 2023-12-11 09:00 pm | American Society Of Hematology Meeting - Poster Number: 4859 |
| 2023-12-10 02:00 pm | American Society of Hematology Meeting - Key Opinion Leader |
| 2023-12-09 08:30 pm | American Society Of Hematology Meeting - Poster Number: 2113 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 896 924 -3.07% | 530 484 9.64% | 485 483 0.39% | 505 545 -7.33% | 784 550 42.49% | 337 |
|
EBITDA Million EUR | Released Forecast Spread | 383 438 -12.64% | -160 -183 12.71% | -131 -213 38.45% | -202 -137 -47.34% | 0,00 -230 - | -115 |
|
EBIT Million EUR | Released Forecast Spread | 370 417 -11.29% | -179 -241 25.85% | -166 -221 25.16% | -268 -192 -39.01% | 129 -148 187.11% | -119 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 150 256 -41.49% | -310 -283 -9.58% | -123 -194 36.75% | -215 -71,5 -200.9% | 0,00 8,44 - | -33,4 |
|
Net income Million EUR | Released Forecast Spread | 150 270 -44.5% | -305 -316 3.45% | -103 -176 41.37% | -218 -69,5 -213.65% | 212 -52,8 500.82% | -44,0 |
|
EPS EUR | Released Forecast Spread | 2,49 5,29 -52.9% | -4,69 -4,33 -8.41% | -1,58 -2,55 37.97% | -3,32 -1,08 -206.08% | 3,21 -1,58 302.72% | -0,96 |
| Announcement Date | 20/02/20 | 18/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 143 132 9.05% | 144 86,6 66.29% | 138 119 15.45% | 274 111 146.85% | 136 121 12.9% | 95,1 99,3 -4.2% | 179 107 66.77% | 150 113 33.19% | 120 102 18% | 335 110 203.65% | 61,6 | 60,7 | 61,2 | 59,7 | 64,6 |
|
EBITDA Million EUR | Released Forecast Spread | 15,8 -34,7 145.55% | -44,0 -43,7 -0.84% | -111 -60,1 -84.28% | -60,0 | -136 | -209 | |||||||||
|
EBIT Million EUR | Released Forecast Spread | 10,2 -49,4 120.65% | -21,1 -50,1 57.87% | -76,4 -39,3 -94.5% | -97,5 -54,0 -80.56% | -37,6 -99,0 62.03% | -132 -58,3 -127.21% | 22,0 -75,2 129.23% | -10,7 -53,8 80.13% | -30,2 -60,2 49.77% | 148 -77,3 291.41% | -38,0 | -34,1 | -30,5 | -37,4 | -11,9 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 19,1 -55,5 134.4% | -11,6 -50,4 76.98% | -18,2 -46,6 60.93% | 22,2 -104 121.49% | -208 -43,5 -376.86% | 23,5 -56,9 141.24% | 18,5 -43,5 142.41% | 25,7 -70,4 136.53% | -101 | -8,61 | -5,09 | -3,95 | -12,6 | 3,86 | |
|
Net income Million EUR | Released Forecast Spread | 16,4 -55,7 129.38% | -13,3 -50,4 73.6% | -19,0 -45,4 58.18% | 21,5 -104 120.77% | -207 -42,7 -384.88% | 23,2 -57,4 140.4% | 5,10 -43,6 111.69% | 25,8 -59,2 143.6% | 158 -72,0 318.95% | -8,61 | -5,09 | -3,95 | -12,6 | 3,86 | |
|
EPS EUR | Released Forecast Spread | 0,25 -0,51 149.22% | -0,29 -0,73 60.14% | 0,33 -0,80 141.25% | -3,16 -0,60 -426.67% | 0,08 -0,86 109.26% | 0,39 -1,70 122.9% | 2,39 -3,72 164.29% | ||||||||
| Announcement Date | 24/02/22 | 05/05/22 | 04/08/22 | 04/08/22 | 03/11/22 | 23/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 22/02/24 | - | - | - | - | - |
More events
Past sector events for Galapagos NV
| 2024-04-17 | HINOVA PHARMACEUTICALS INC.: Q4 2023 Earnings Release |
| 2024-04-17 02:07 am | TELIX PHARMACEUTICALS LIMITED: March 2024 Sales and Revenue Release - Activities Report |
| 2024-04-10 04:10 pm | PHARVARIS N.V.: Q4 2023 Earnings Release |
| 2024-04-10 01:22 am | POLARIS GROUP: March 2024 Sales and Revenue Release |
| 2024-04-02 02:30 am | ABIVAX: Q4 2023 Earnings Release |
| 2024-04-01 09:00 am | BIOMEA FUSION, INC.: Q4 2023 Earnings Release |
| 2024-03-28 10:42 pm | ALPHAMAB ONCOLOGY: Q4 2023 Earnings Release |
| 2024-03-28 04:28 pm | CENTESSA PHARMACEUTICALS PLC: Q4 2023 Earnings Release |
| 2024-03-28 04:05 pm | ARRIVENT BIOPHARMA, INC.: Q4 2023 Earnings Release |
| 2024-03-28 07:10 am | HANGZHOU TIGERMED CONSULTING CO., LTD: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- GLPG Stock
- Calendar Galapagos NV
